{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:39:22Z","timestamp":1790375962173,"version":"4.1.0"},"reference-count":51,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"No funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2018,8,3]]},"DOI":"10.1080\/13543784.2018.1498081","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T04:39:58Z","timestamp":1531456798000},"page":"691-697","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma"],"prefix":"10.1080","volume":"27","author":[{"given":"Carrie","family":"Van Der Weyden","sequence":"first","affiliation":[{"name":"Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Saint-Louis, Paris, France"},{"name":"Inserm U976, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Neeson","sequence":"additional","affiliation":[{"name":"Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil K.","family":"Darcy","sequence":"additional","affiliation":[{"name":"Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[{"name":"Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia"},{"name":"Epworth Healthcare, Richmond, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,7,17]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184168"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.7.857"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.048"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-611830"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.7665"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0604"},{"issue":"6","key":"CIT0008","first-page":"vi149","volume":"24","author":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, Group EGW","year":"2013","journal-title":"Ann Oncol"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.01.025"},{"issue":"2","key":"CIT0011","doi-asserted-by":"crossref","first-page":"ii72","DOI":"10.1093\/annonc\/mdn095","volume":"19","author":"Dummer R, Dreyling M, Group EGW","year":"2008","journal-title":"Ann Oncol"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-588236"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2802"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00143.x"},{"issue":"5","key":"CIT0015","first-page":"702","volume":"90","author":"Zinzani PL","year":"2005","journal-title":"Haematologica"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11127"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903216770"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003008"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12690"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3575"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/11.1.81"},{"issue":"10","key":"CIT0022","first-page":"3625","volume":"9","author":"Ishida T","year":"2003","journal-title":"Clin Cancer Res"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-600924"},{"issue":"1","key":"CIT0025","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V130.Suppl_1.817.817","volume":"130","author":"Kim YH","year":"2017","journal-title":"Blood"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3969"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3787"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-24"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1456"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1997.tb00943.x"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1002\/art.21395"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1388"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.22326.x"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4239"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20395"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09364.x"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.356"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3185"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2012.01489.x"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14626"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792382"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-598995"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.286"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4631"},{"key":"CIT0047","volume-title":"IPH4102, the first-in-class anti-KIR3DL2 mAb, is safe and clinically active in advanced cutaneous T-cell lymphoma (CTCL) patients: results from the dose-escalation part of the IPH4102\u2013101 phase I study","author":"Bagot M","year":"2017"},{"key":"CIT0048","volume-title":"Biomarkers of pharmacological and clinical activity of IPH4102, first-in-class humanized anti-KIR3DL2 mAb, in a phase I study in patients with relapsed\/refractory CTCL","author":"Battistella M","year":"2017"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_31"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.2.273"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00122-14"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16322"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2018.1498081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T12:59:12Z","timestamp":1661605152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2018.1498081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,17]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,7,17]]},"published-print":{"date-parts":[[2018,8,3]]}},"alternative-id":["10.1080\/13543784.2018.1498081"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2018.1498081","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}